Expert Review of Hematology
Volume 14, 2021 - Issue 7
Review
Oral ferroportin inhibitor vamifeport for improving iron homeostasis and erythropoiesis in β-thalassemia: current evidence and future clinical development
John Portera Professor of Haematology, Department of Haematology, University College London, Consultant in Haematology, University College London Hospitals and Head of Joint UCLH and Whittington Hospital Red Cell Unit, London, UK
https://orcid.org/0000-0003-3000-9359View further author information
https://orcid.org/0000-0003-3000-9359View further author information, Ali Taherb Professor of Medicine, Hematology and Oncology, Division of Hematology and Oncology, Department of Internal Medicine, American University of Beirut Medical Center, Beirut, Lebanonhttps://orcid.org/0000-0001-8515-2238View further author information
https://orcid.org/0000-0001-8515-2238View further author information, Vip Viprakasitc Professor of Pediatrics, Director, Thalassemia Research Program, Director, SiCORE in Advanced Cell & Gene Therapy Center (SiCORE-ACGT), Division of Hematology and Oncology, Department of Pediatrics & Siriraj Thalassemia Center, Faculty of Medicine Siriraj Hospital, Mahidol University, Bangkok, Thailandhttps://orcid.org/0000-0003-3162-1849View further author information
https://orcid.org/0000-0003-3162-1849View further author information, Antonis Kattamisd Professor of Pediatric Hematology-Oncology, Division of Pediatric Hematology-Oncology, First Department of Pediatrics, National and Kapodistrian University of Athens, Athens, Greecehttps://orcid.org/0000-0002-5178-0655View further author information
https://orcid.org/0000-0002-5178-0655View further author information, Thomas D Coatese Section Head, Hematology, Cancer and Blood Disease Institute, Professor of Pediatrics and Pathology, Children’s Hospital Los Angeles, University of Southern California Keck School of Medicine, Los Angeles, CA, USAhttps://orcid.org/0000-0001-9878-6029View further author information
https://orcid.org/0000-0001-9878-6029View further author information, Maciej Garbowskif Clinical Research Fellow, Department of Haematology, University College London Cancer Institute, London, UKhttps://orcid.org/0000-0001-6441-9562View further author information
https://orcid.org/0000-0001-6441-9562View further author information, , Vania Manolovah Head of Biology R&D, Vifor (International) AG, Chemical and Preclinical Research and Development, St. Gallen, Switzerlandhttps://orcid.org/0000-0002-2072-8942View further author information
https://orcid.org/0000-0002-2072-8942View further author information, Frank Richardi Clinical Research Director, Vifor Pharma AG, Glattbrugg, Switzerlandhttps://orcid.org/0000-0003-1027-3814View further author information
https://orcid.org/0000-0003-1027-3814View further author information & M. Domenica Cappellinij Professor of Internal Medicine, Department of Clinical Sciences and Community, University of Milan, Milan, ItalyCorrespondence[email protected]
https://orcid.org/0000-0001-8676-6864View further author information
https://orcid.org/0000-0001-8676-6864View further author information show all